膜联蛋白A1通过促进炎症消退减轻糖尿病肾病肾损伤
本研究探讨内源性膜联蛋白A1(ANXA1)在糖尿病肾病中的作用。发现患者肾脏ANXA1表达上调且与肾功能及肾脏结局相关;在糖尿病小鼠中,ANXA1缺失加重肾损伤,过表达或给予模拟肽Ac2-26可减轻损伤,机制涉及ANXA1结合NF-κB p65抑制其激活。
要点
- 糖尿病肾病患者肾脏ANXA1表达上调,且与肾功能和肾脏结局相关。
- ANXA1缺失加重糖尿病小鼠肾损伤,过表达或Ac2-26治疗可减轻损伤。
- ANXA1通过结合NF-κB p65抑制其激活,调节炎症状态。
核心结论
- ANXA1可能成为治疗和逆转糖尿病肾病的有前景的治疗靶点。
研究设计与样本
- 研究纳入糖尿病肾病患者肾脏标本,并在高脂饮食/链脲佐菌素诱导的糖尿病小鼠及db/db小鼠中评估ANXA1的作用。
主要发现
- 糖尿病肾病患者肾脏ANXA1水平上调,且与肾功能及肾脏结局相关。
- ANXA1缺失加重糖尿病小鼠肾损伤,表现为更严重的白蛋白尿、系膜基质扩张、肾小管间质病变、肾脏炎症和纤维化。
- ANXA1过表达改善糖尿病肾病小鼠肾损伤;Ac2-26减轻db/db小鼠和糖尿病Anxa1敲除小鼠的肾损伤。
- 机制上,细胞内ANXA1结合转录因子NF-κB p65亚基,抑制其激活,从而调节炎症状态。
临床怎么用
- ANXA1及其模拟肽Ac2-26可能作为糖尿病肾病的新型治疗策略,但尚未进入临床实践。
局限性
- 研究主要基于动物模型和患者组织样本,ANXA1在人体中的治疗潜力需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since failed resolution of inflammation is a major contributor to the progression of diabetic nephropathy, identifying endogenously generated molecules that promote the physiological resolution of inflammation may be a promising therapeutic approach for this disease. Annexin A1 (ANXA1), as an endogenous mediator, plays an important role in resolving inflammation. Whether ANXA1 could affect established diabetic nephropathy through modulating inflammatory states remains largely unknown. In the current study, we found that in patients with diabetic nephropathy, the levels of ANXA1 were upregulated in kidneys, and correlated with kidney function as well as kidney outcomes. Therefore, the role of endogenous ANXA1 in mouse models of diabetic nephropathy was further evaluated. ANXA1 deficiency exacerbated kidney injuries, exhibiting more severe albuminuria, mesangial matrix expansion, tubulointerstitial lesions, kidney inflammation and fibrosis in high fat diet/streptozotocin-induced-diabetic mice. Consistently, ANXA1 overexpression ameliorated kidney injuries in mice with diabetic nephropathy. Additionally, we found Ac2-26 (an ANXA1 mimetic peptide) had therapeutic potential for alleviating kidney injuries in db/db mice and diabetic Anxa1 knockout mice. Mechanistic studies demonstrated that intracellular ANXA1 bound to the transcription factor NF-κB p65 subunit, inhibiting its activation thereby modulating the inflammatory state. Thus, our data indicate that ANXA1 may be a promising therapeutic approach to treating and reversing diabetic nephropathy.
引用
- Wu L, Liu C, Chang DY, et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney Int. 2021. PMID: 33675846. doi:10.1016/j.kint.2021.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。